Immuron Reports Unaudited Sales Growth for Q1 FY27
Immuron Limited announced double-digit sales growth for the quarter ending September 30, 2026, driven by strong performance of its Travelan product in Australia.
Stocks · News reference
Immuron Announces Exclusive U.S. Distribution Agreement For Calmino Group's Digestive Health Product PROIBS
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference
Immuron Limited announced that its CEO, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on October 28, 2026.
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
Immuron Limited announced that Chief Executive Officer Steven Lydeamore will present virtually at the Emerging Growth Conference on October 28, 2026. The presentation will focus on the company's biopharmaceutical pipeline, including its lead product Travelan® for travelers' diarrhea, IMM-529 for Clostridioides difficile infection, and the ProIBS® distribution agreement in Australia and New Zealand.
Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo
Immuron Limited ((ASX: IMC, NASDAQ:IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports.A copy of the publication can
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results
U.S. stocks fell as August jobs beat estimates; oil, gold and silver declined. Immuron, Quanex and AOUT surged, while GWRE, LULU and PATH dropped.
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August
U.S. stocks mixed as Dow and S&P fell despite strong August job gains; tech rose, energy slid, and oil, gold and silver declined.